NASDAQ: MPLTMaplight Therapeutics Inc Stock
$16.55-0.20 (-1.19%)
Updated Oct 29, 2025
MPLT Price
$16.55
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$15.00
52 Week High
$20.86
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.08
Operating Cash Flow
N/A
Beta
-32.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MPLT Overview
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MPLT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MPLT
Ranked#200 of 488
Ranked#200 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.17 | A | |
| $12.22 | A | |
| $7.19 | A |
Be the first to know about important MPLT news, forecast changes, insider trades & much more!
MPLT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MPLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MPLT's short-term assets ($73.20M) exceed its short-term liabilities ($14.98M)
Short-term Liabilities Financials
MPLT's short-term assets ($73.20M) exceed its long-term liabilities ($5.37M)
Long-term Liabilities Financials
MPLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more MPLT due diligence checks available for Premium users.
Valuation
MPLT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$84.1M
Liabilities
$20.4M
Debt to equity
-0.08
MPLT's short-term assets ($73.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MPLT's short-term assets ($73.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MPLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MPLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MPLT vs Biotech Stocks
Maplight Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.